Brief: OSE Immunotherapeutics Gets First Notice Of Allowance For U.S. Patent On Antibody For Cancer Treatment

Ose Immunotherapeutics SA

21/03/2022 17:11

March 21 (Reuters) - OSE Immunotherapeutics SA  OSE.PA :
    * OSE IMMUNOTHERAPEUTICS RECEIVES FIRST NOTICE OF ALLOWANCE
FOR A
US PATENT COVERING ANTI-PD1 MONOCLONAL ANTIBODY OSE-279 AND ITS
USE IN CANCER TREATMENT
    * ANNOUNCES THAT THE UNITED STATES PATENT AND TRADEMARK
OFFICE
(USPTO) HAS ISSUED A FIRST NOTICE OF ALLOWANCE FOR A PATENT
APPLICATION
    * NEW PROTECTION COVERING OSE-279 UNTIL 2039
    * WE LOOK FORWARD ADVANCING OUR ANTI-PD1 BACKBONE
DEVELOPMENT WITH
PHASE 1 CLINICAL TRIAL PLANNED TO START IN 2022 - CEO

Source text for Eikon:  ID:nBwbsQhkja 
Further company coverage:  OSE.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))